References
- 1..Needham M,Corbett A,Day T,Christiansen F,Fabian V,Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci. 2008;15(12):1350-3.
- 2..Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-72.
- 3..Mamouris P,Nassiri V,Molenberghs G,van den Akker M,van der Meer J,Vaes B. Fast and optimal algorithm for case-control matching using registry data: application on the antibiotics use of colorectal cancer patients. BMC Med Res Methodol. 2021;21(1):62.
- 4..Naddaf E,Shelly S,Mandrekar J,Chamberlain AM,Hoffman EM,Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology. 2022;61(5):2016-24.
- 5..Cox FM,Titulaer MJ,Sont JK,Wintzen AR,Verschuuren JJ,Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167-75.

